Hikal posts FY23 PAT at Rs. 36 Cr
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
The PP-based top and bottom webs are manufactured in a unique coextrusion process
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
Continues to Expand its Presence in South India
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
Subscribe To Our Newsletter & Stay Updated